Lured By Rising Transplant Cases, Astellas Finally Brings Prograf To India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Japan's second-largest drug maker Astellas is bringing into India its flagship organ transplant drug Prograf (tacrolimus) in a bid to tap the Asian giant's steadily growing domestic pharmaceutical market. The product registration application for Prograf is pending with the Drug Controller General of India and Astellas hopes to launch the drug by the end of the current financial year